BAYN.DE Bayer Aktiengesellschaft
Company Analysis
Latest News
🟢 BAYN.DE is trading 2.8% up today as Supreme Court ruling scales back Roundup litigation risk
BAYN.DE is trading 2.8% up today at $47.97 after a U.S. Supreme Court decision to scale back Roundup cancer lawsuits in the company's favor. • The ruling...
🟢 BAYN.DE is trading 19% up today after U.S. Supreme Court ruling limits Roundup liability
BAYN.DE is trading 19% up at $47.00 after a landmark U.S. Supreme Court decision sharply reduced its Roundup legal overhang. • The Court ruled 7–2 that...
Bayer Surges 16% After Supreme Court Shields It From Roundup Cancer Lawsuits — But Can a Legal Victory Alone Fix a €30 Billion Debt Problem?
Shares of Bayer exploded higher on June 25 after the U.S. Supreme Court delivered the ruling the company has sought for years. In a 7-2 decision, the Court...
🟢 BAYN.DE is trading 16% up today on Roundup litigation optimism and higher analyst price targets
BAYN.DE is trading 16% up today at $45.79, sharply outperforming a mixed broader market as sentiment improves regarding its U.S. Roundup litigation overhang...
🟢 Bayer Aktiengesellschaft is trading 4.8% up today following a favorable Roundup settlement ruling and the completion of Perfuse Therapeutics acquisition
Bayer Aktiengesellschaft is trading at $37.74 (+4.80%) following several key developments on June 17, 2026, including a broader market rally. • A federal...
🟢 Bayer Aktiengesellschaft extends move to 6.9% up
BAYN.DE is trading at $38.44, up 6.9% versus the comparison close of $35.96 during regular trading. This is a price-movement alert; no separate...
🟢 Bayer Aktiengesellschaft is trading 3.6% up today after FDA approval of MRI contrast agent Ambelvist
Bayer Aktiengesellschaft is trading 3.6% up today at $37.44 following the FDA approval of its new MRI contrast agent, Ambelvist (gadoquatrane). • The June 16,...
Bayer wins FDA approval for Ambelvist, the lowest-dose MRI contrast agent
The U.S. Food and Drug Administration (FDA) approved Bayer’s new intravenous macrocyclic gadolinium-based contrast agent, gadoquatrane. Bayer will market the...
Bayer Advances Asundexian to EU Review, Seeking First-in-Class Stroke Approval
The European Medicines Agency (EMA) accepted Bayer’s marketing authorization application for asundexian. This validation confirms the submission is complete...
Bayer Kerendia slows kidney disease, marking fifth straight Phase III success
Bayer reported positive Phase III FIND-CKD trial results for its drug Kerendia (finerenone). The drug significantly slowed kidney disease progression in...
🔴 Bayer Aktiengesellschaft is trading 5.2% down today on fresh Roundup settlement uncertainty
Bayer Aktiengesellschaft is trading 5.2% down at €33.30 after fresh uncertainty emerged regarding its proposed $7.25 billion U.S. Roundup weedkiller...
🔴 Bayer (BAYN.DE) slumps over 5% on renewed uncertainty over $7.25B Roundup settlement
Bayer Aktiengesellschaft is trading at €33.30 (-5.21%) after news of a fresh legal obstacle in the company's long-running Roundup weedkiller litigation renewed...
Bayer NUBEQA Beats Rival on Cognitive Safety in Prostate Cancer Trial
Bayer presented primary Phase II ARACOG trial results at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The head-to-head study met its...
Bayer Faces Antitrust Lawsuit, Allegedly Blocking Generic GMO Corn Seeds
Iowa-based Latham Quality Seed filed a federal antitrust lawsuit against Bayer for allegedly monopolizing the genetically modified (GMO) corn seed market. The...
Bayer $7.25 billion Roundup settlement stalls, following federal court move
Bayer faces potential delays for its proposed $7.25 billion settlement involving thousands of Roundup cancer claims. An opposing attorney escalated legal...